Five years ago, a study of death certificate data attracted notice for suggesting that states that passed medical marijuana laws saw 25 percent fewer... A cautionary tale about medical marijuana and opioid deaths

Five years ago, a study of death certificate data attracted notice for suggesting that states that passed medical marijuana laws saw 25 percent fewer opioid overdose deaths on average than states that barred medical cannabis.

The authors were careful to point out that this finding was only a correlation, an intriguing hint at something that needed further exploration. There was no way to establish whether the availability of medical cannabis in some states protected against overdosing on harder drugs, even if some people used marijuana for pain.

Nevertheless, the cannabis industry took up the study to help win passage of medical cannabis laws in more states, even as medical experts expressed skepticism. In a 2018 report, for example, Maryland’s medical marijuana commission found “no credible scientific evidence” that marijuana could treat opioid addiction.

Now comes a study from Stanford University School of Medicine showing that when researchers looked at a longer period of time, states that introduced medical marijuana actually had 23 percent more deaths from opioid overdoses.

The new work appears to be a cautionary tale about inferring cause and effect — wanting research to show something it can’t because the nation is in the grip of a deadly opioid epidemic or because there is money to be made by offering possible solutions. [Read More @ The Washington Post]

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

No comments so far.

Be first to leave comment below.




( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )